

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE et al
				Group Art Unit	1614
				Examiner Name	Theresa Frederick
Sheet	2	Of	4	Attorney Docket Number	031896-004000 (100990)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
KS		THEOFILOPOULUS, A. N., <i>The Basis Of Autoimmunity: Part II. Genetic Predisposition, Immunology Today</i> 15:150-58, 1995)			
		SUN et al., <i>J. Neuropathol Exp Neurol</i> , 56:1339-1348, 1997			
		KADOMATSU et al., <i>Br J Cancer</i> , 75:354-359, 1997			
		CHOUDHURI et al., <i>Cancer Res.</i> , 75:354-359, 1997			
		TAKEI et al., <i>Cancer Res.</i> , 61:8486-8491, 2001			
		TAKEI et al., <i>J. Biol Chem Embo J</i> , 16:6936-6946, 1997			
		INUI, TATSUYA, et al., Peptide Institute Inc., <i>J Pept Sci</i> 2:28-39, 1996			
		MURAMATSU et al., <i>Biochem Biophys Res Commun</i> 203:1131-1139, 1994			
		ASAI et al., <i>Biochem Biophys Res Commun</i> , 203:1131-1139, 1994			
		KANEDA et al., <i>Biochem Biophys Res Commun</i> , 220:108-112, 1996			
		PEDRAZA et al., <i>J Biochem</i> , 117: 845-849, 1995			
		AHMED et al., <i>Cancer Lett</i> , 180: 159-63, 2002			
		AHMED et al., <i>Int. J. Mol. Med.</i> , 6:281-287, 2000			
		URIOS et al., <i>Biochem Biophys Res Commun</i> 175: 617-627, 1991			
		NAIR et al., <i>Neuroscience</i> , 85:759-771, 1998			

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				10/686,619	
				Filing Date	
				October 17, 2003	
				First Named Inventor	
		Margot Mary O'TOOLE et al.			
Art Unit		1614			
Examiner Name		Theresa Frederick			
Attorney Docket Number		031896-004000 (AM100990)			
Sheet	3	Of	4		

KS	SUI et al., <i>Proc. Nat'l. Acad. Sci. USA</i> , 99: 5515-5520, 2002	
	LEE et al., <i>Nature Biotechnology</i> , 20:500-505, 2002	
	NEEDLEMAN and WUNSCH, <i>J. Mol. Biol.</i> , 48:444-453, 1970	
	ALTSCHUL et al., <i>Polynucleotides Res</i> 25 (17): 3389-3402, (1997).	
	MARATEA et al., <i>Gene</i> , 40:39-46, 1985	
	MURPHY et al., <i>Proc. Nat'l Acad. Sci. USA</i> , 83:8258-8262, 1986	
	DELGRAVE et al., <i>Protein Engineering</i> , 6: 327-331, 1993	
	GOSSEN et al., <i>Science</i> , 268: 1766-1769, 1995	
	NO et al., <i>Proc. Nat'l. Acad. Sci. USA</i> , 93: 3346-3351, 1996	
	WANG et al., <i>Nat. Biotech</i> , 15: 239-243, 1997	
	YE et al., <i>Science</i> 283: 88-91, 1999	
	ZUCKERMANN et al. 1994, <i>J. Med. Chem.</i> 37:2678-85	
	LAM, <i>Anticancer Drug Des.</i> , 12: 145, 1997	
	GUATELLI et al., <i>Proc. Natl. Acad. Sci. USA</i> , 87: 1874-1878, 1990	
	KWOH et al., <i>Proc. Natl. Acad. Sci. USA</i> , 86: 1173-1177, 1989	
✓	LIZARDI et al. Q-Beta Replicase, <i>Bio-Technology</i> 6: 1197, 1988	


Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE et al.
				Art Unit	1614
				Examiner Name	Theresa Frederick
Sheet	4	Of	4	Attorney Docket Number	031896-004000 (AM100990)

KS		MYERS et al., <i>Science</i> , 230: 1242, 1985	
		KEEN et al., <i>Trends Genet</i> , 7:5, 1991	
		ROSENBAUM and REISSNER, <i>Biophys Chem</i> 265: 12753, 1987	
		SAIKI et al., <i>Proc. Natl. Acad. Sci USA</i> , 86:6230, 1989	
		O'GORMAN et al., <i>Science</i> , 251:1351-1355, 1991	
		WILMUT, I. et al., <i>Nature</i> 385:810-813, 1997	
		LOCKHART et al., <i>Nature Biotechnology</i> , 14, 1675-80, 1996	
↓		HILL et al., <i>Genome Biol. 2 Res</i> , 0055.1-0055.13, 2001	

Examiner Signature	/Katherine Salmon/	Date Considered	08/24/2006
--------------------	--------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/686,619
		Filing Date	October 17, 2003
		First Named Inventor	Margot Mary O'TOOLE et al.
		Art Unit	1614
		Examiner Name	Theresa Frederick
		Attorney Docket Number	031896-004000 (AM100990)
Sheet	1	of	2

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
KS		EP 1 215 500 A	06-19-2002	Muramatsu		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS		MISHIMA, et al., "Increased expression of midkine during the progression of human astrocytomas", <i>Neuroscience Letters</i> , Vol., 233, No. 1, pages 29-32, (1997)	
		TSUTSUI, et al., "A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas", <i>Cancer Research</i> , Vol. 53, No. 6, pages 1281-1285, (1993)	
		KUROSAWA, et al., "Midkine binds specifically to sulfatide. The role of sulfatide in cell attachment to midkine-coated surfaces", <i>European Journal of Biochemistry</i> , Vol. 267, No. 2, January 2000	
		ZOU, et al., "A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican", <i>European Journal of Biochemistry</i> , Vol. 267, No. 13, July 2000	
		SAID, et al., "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 40, pages 37492October 4, 2002	
		STOICA, et al., "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 39, pages 35990-35998, September 27, 2002	
		IKEDA, et al., "Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence", <i>Biology of Reproduction</i> , Vol. 63, No. 4, pages 1067-1074, October 2000	



Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/686,619		
		Filing Date	October 17, 2003		
		First Named Inventor	Margot Mary O'TOOLE et al.		
		An Unit	1614		
		Examiner Name	Theresa Frederick		
Sheet	2	of	2	Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS		KATO, et al., "Increased midkine expression in intrahepatic cholangiocarcinoma: Immunohistochemical and in situ hybridization analyses", <i>Liver</i> , Vol. 20, No. 3, June 2000	
KS		TSUTSUI, et al., "A New Family of Heparin-Binding Factors Strong Conservation of Midkine MK Sequences Between the Human and the Mouse", <i>Biochemical and Biophysical Research Communications</i> , Vol. 176, No. 2, pages 792-797,	

Examiner Signature	/Katherine Salmon/	Date Considered	09/05/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
				Art Unit	1614
				Examiner Name	Theresa Frederick
Sheet	1	of	1	Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ² (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS		International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages	
		ASAI, T. <i>et al.</i> , "Identification of heparin-binding sites in midkine and their role in neurite-promotion," <i>Biochem. Biophys. Res. Commun.</i> , 236(1):66-70 (1997)	
		IWASAKI, W. <i>et al.</i> , "Solution structure of midkine, a new heparin-binding growth factor," <i>EMBO J.</i> , 16(23):6936-6946 (1997)	
		MYERS, E.W. and MILLER, W., Optical alignments in linear space, <i>CABIOS</i> , 4(1):11-17 (1988)	
		MURAMATSU, H. <i>et al.</i> , "Localization of heparin-binding, neurite outgrowth and antigenic regions of midkine molecule," <i>Biochem. Biophys. Res. Commun.</i> , 203(2):1131-1139 (1994)	
		TAKEI, Y. <i>et al.</i> , "5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine, its design and application for cancer therapy," <i>J. Biol. Chem.</i> , 277(26):23800-23806 (2002)	

Examiner Signature	/Katherine Salmon/	Date Considered	08/24/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Jennifer Shin Shin Wong
Sheet	1	of	2	Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials ²	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ³ (if known)			
KS		U.S. - 4,554,101	11-19-1985	HOPP, T. P.	
KS		U.S. - 2003/0148298 A1	08-07-2003	O'TOOLE, M. <i>et al.</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials ²	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ⁵ Number ⁴ Kind Code ³ (if known)				
KS		WO 2004/036221 A2	04-29-2004	O'TOOLE <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
KS		FRAMPTON, G. <i>et al.</i> , Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen, <i>Rheumatology (Oxford)</i> , 39(10):1114-1120, 2000	
		ADACHI, M., <i>et al.</i> , Correlation of KA11/CD82 gene expression with good prognosis in patients with non-small cell lung cancer, <i>Cancer Res.</i> , 56(8):1751-1755, 1996	
		DUAN, J. <i>et al.</i> , Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis, <i>FEBS Lett.</i> , 499(1-2):127-132, 2001	
		HAMMOND, C. <i>et al.</i> , The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules, <i>J. Immunol.</i> , 161(7):3282-3291, 1998	
		HECKENLIVELY, J. R. <i>et al.</i> , Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration, <i>Arch. Ophthalmol.</i> , 118(2):1525-1533, 2000	
		LAGAUDRIERE-GESBERT, C. <i>et al.</i> , The tetraspanin protein CD82 associates with both free HLA class I heavy chain and heterodimeric beta 2-microglobulin complexes, <i>J. Immunol.</i> , 158(6):2790-2797, 1997	
		LEBEL-BINAY, S. <i>et al.</i> , CD82, member of the tetra-span-transmembrane protein family, is a costimulatory protein for T cell activation, <i>J. Immunol.</i> , 155(1):101-110, 1995	
✓		MAEDA, A. <i>et al.</i> , Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice, <i>Eur. J. Immunol.</i> , 32:2300-2307, 2002	

Examiner Signature	/Katherine Salmon/	Date Considered	09/05/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number		10/686,619
				Filing Date		October 17, 2003
				First Named Inventor		Margot Mary O'TOOLE <i>et al.</i>
				Art Unit		1634
				Examiner Name		Jennifer Shin Shin Wong
Sheet	2	of	2	Attorney Docket Number		031896-004000 (AM100990)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS		ROTH, W. <i>et al.</i> , Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells, <i>Oncogene</i> , 19(37):4210-4220, 2000	
		XU, N. <i>et al.</i> , Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells, <i>Biochem. Biophys. Res. Commun.</i> , 292(4):944-950, 2002	
		XU, N. <i>et al.</i> , A novel human apolipoprotein (apoM), <i>J. Biol. Chem.</i> , 274(44):31286-31290, 1999	
		YOSHINO, K. <i>et al.</i> , Secreted Frizzled-related proteins can regulate metanephric development, <i>Mech. Dev.</i> , 102(1-2):45-55, 2001	
		LEE, N. S. <i>et al.</i> , Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, <i>Nat. Biotechnol.</i> , 20(5):500-505, 2002	
		BAZHIN, A. V. <i>et al.</i> , Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision, <i>Lung Cancer</i> , 34(1):99-104, 2001	
		International Search Report for International Application No. PCT/US2004/005655, mailed November 8, 2004, 6 sheets	
		ROZZO, S. J. <i>et al.</i> , Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus, <i>Immunity</i> , 15(3): 435-443, 2001	
		MOSER, K. L. <i>et al.</i> , The use of microarrays to study autoimmunity, <i>J. Investig. Dermatol. Symp. Proc.</i> , 9(1):18-22, 2004	
V		BENNETT, L. <i>et al.</i> , Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, <i>J. Exp. Med.</i> , 97(6):711-723, 2003	

Examiner Signature	/Katherine Salmon/	Date Considered	09/05/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.